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Abstract
Background: Adherence to interferon b-1b (INFb-1b) therapy is essential to maximize the beneficial effects of treatment in
multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFb-1b in patients
suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice.
Methodology/Principal Findings: This was an observational, retrospective, cross-sectional study including 120 Spanish
patients with MS under INFb-1b treatment. Therapeutic adherence was assessed with Morisky-Green test and with the
percentage of doses received. The proportion of adherent patients assessed by Morisky-Green test was 68.3%, being
indicative of poor adherence. Nevertheless, the percentage of doses received, which was based on the number of injected
medication, was 94.3%. The main reason for missing INFb-1b injections was forgetting some of the administrations (64%).
Therefore, interventions that diminish forgetfulness might have a positive effect in the proportion of adherent patients and
in the percentage of doses received. In addition, age and comorbidities had a significant effect in the number of doses
injected per month, and should be considered in the management of adherence in MS patients.
Conclusion/Significance: Among all the available methods for assessing adherence, the overall consumption of the
intended dose has to be considered when addressing adherence.
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Introduction
Multiple Sclerosis (MS) is a chronic progressive disease of the
central nervous system with a very heterogeneous clinical course
[1]. Clinically, MS usually initiates with an acute inflammatory
demyelinating episode (clinically isolated syndrome – CIS),
suffering later on new clinical episodes turning to relapsing-
remitting MS (RRMS). Many of these patients develop into a
secondary-progressive MS (SPMS) in approximately 10 years time
[2,3]. Alternatively, 10% of patients may suffer from a primary
progressive form of the disease (PPMS) since onset.
Although MS is still an incurable disease, several randomized
clinical trials have demonstrated the benefits of disease modifying
drugs (DMD) in reducing the relapse rate, the rate of disability
progression, and the magnetic resonance imaging (MRI) outcomes
[4–12]. The Multiple Sclerosis Therapy Consensus Group
(MSTCG) [13] recommends early initiation of immunotherapy
with any of these DMDs after the first episode suggestive of MS,
because of its efficacy in preventing and delaying relapses [6].
Immunomodulatory treatments are long-term therapies that
might be difficult to sustain by MS patients over a long period of
time. Then, poor adherence is a critical issue that compromises the
effectiveness of DMD therapies. According to the World Health
Organization (WHO), adherence is the extent to which a person’s
behavior corresponds with agreed recommendations from a health
care provider [14]. Overall, adherence to long-term therapies for
chronic illnesses in developed countries averages 50% [14], and it
accounts for 60% to 90% of patients with MS [15–22]. Most
studies conducted to assess adherence in MS patients have been
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focused on discontinuation rates [15–19,21,22], being side effects,
perception of lack of efficacy, missed disease improvement, or
disease worsening the main reasons to stop treatment [23]. In
these cases, discontinuation is most likely to occur within the first
six months of treatment [24]. Besides discontinuation, adherence
might be focused on prescribed treatment regimen. To date, the
available information to this definition of adherence is limited to
the studies of Tremlett et al. [20] and Devonshire et al. [25] in
which adherence was defined as not missing a single DMD
injection.
As the identification of the factors that affect adherence is the
first step in improving therapeutic compliance, and therefore, in
obtaining the maximum benefits of long-term treatment [25], this
study achieved to assess the adherence to prescribed INFb-1b
treatment in patients with MS in Spain.
Methods
Objectives
This study aimed to assess adherence to prescribed INFb-1b
treatment in patients with MS in Spain, to identify the main
reasons for non-adherence, and to identify factors that may be
responsible for poor adherence in routine clinical practice.
Participants
Eligible patients were those with diagnosis of CIS, RRMS or
SPMS, and those on INFb-1b treatment at recommended doses
for at least six months before the study enrollment. In addition,
eligible patients must have retrieved medication from the hospital
pharmacy, and attend to routine follow-up visits. This study
included patients who consecutively attended to 13 Spanish
centers between October 2008 and February 2009 and met all the
inclusion criteria. The number of patients who were enrolled in
the study was the planned per-protocol. In addition, patients were
recruited by order of attendance to their physician’s to avoid
selection bias
Study design
This is a multicentre, observational, retrospective, cross-
sectional study with a single visit to assess the adherence of MS
patients to INFb-1b treatment in Spain.
Treatment
Interferon b-1b (250 mg/ml) was injected subcutaneously (SC)
every other day (EOD) during at least six months before to the
study enrollment.
Variables and measurements
The main variable of the study was self-reported adherence to
INFb-1b in the previous four weeks assessed by Morisky-Green
(MG) test [26]. This test was selected because of its reliability
(61%), and because it was validated to the Spanish language [27].
In addition, MG test assess attitudes towards treatment. According
to MG test, patients were fully adherent when correctly answered
the four-item questionnaire: Had you ever forgotten to inject your
medication? (NO); are you rigorous in regard to your injection
hours? (YES); do you skip your injection hours when you are
feeling well? (NO); and when you feel worse due to the medicine,
do you skip your injection? (NO).
Adherence was also evaluated by means of the percentage of
doses received that was calculated by dividing the number of self-
administered injections by the number of injections that should
have been administered in the previous four weeks.
In addition, the number of injections dispensed by the hospital
pharmacy during the previous six months, and the number of
forgotten injections, as well as reasons for forgetting them during
the previous month were assessed.
Other variables recorded were demographic data (age, sex,
marital status, education level, employment status), MS clinical
data (MS diagnosis, age at first episode, age at diagnosis, time since
last relapse), clinical setting characteristics (existence of MS unit),
MS treatment (time on INFb-1b therapy), general health status
(existence of anxiety/depression (yes/no), regular fatigue (yes/no),
comorbidities, and concomitant treatments), and adverse events.
The Expanded Disability Status Scale (EDSS) [28] were used to
assess the degree of disability caused by MS.
Statistical analysis
Descriptive statistical analyses were performed by means of the
software SASH 9.1.3. Continuous variables were described by
means of their average and standard deviation (SD), while
categorical variables were described by counts (N) and frequencies.
The relationship between baseline variables (demographic, clini-
cal, and clinical setting characteristics) and adherence was
analyzed. For that reason, patients were divided into two
categories: adherent and non-adherent. The differences between
study groups were done by chi-square test for categorical variables,
and t-Student test or analyses of variance (ANOVA) for
continuous variables at a significant level p,0.05.
Additionally, the effect of baseline variables (predictor variables)
on the number of injections administered during the previous
month was studied by means of a univariate regression model.
Afterwards, the significant predictor variables were used in a final
multivariate regression model.
Ethics
The local ethical review board of Hospital Universitario Carlos
Haya de Ma´laga approved the protocol of the study according to
the principles of the Declaration of Helsinki. All patients had
received detailed information on the study and had provided their
written informed consent prior to their inclusion.
Results
Baseline demographic and clinical data
Baseline demographic and clinical data are summarized in
Table 1. A total of 120 patients (64.2% females) were enrolled at
13 Spanish centers. Overall, patients had been suffering from MS
for an average time of 11.768.9 years, and most of them were
suffering from RRMS.
Treatment
Patients were treated for an average of 5.364.5 years, and
titration was used in 75% of them. INFb-1b was used at the
standard dose of 250 mg/ml EOD, 85.8% of the patients self-
injected INF-1b medication, usually using an auto-injector
(91.7%), all of them had received previous training by a nurse,
and 52.9% kept regularly a record of the date of injections.
Adherence to INFb-1b
According to MG test, the proportion of patients adherent to
treatment was of 68.3% (82/120 patients). Among these patients,
79.2% (95/120) of them had never forgotten to take any injection,
and among the remaining adherent patients (20.8% [25/120]),
56.5% had forgotten only one injection). Among the 31.7% (38/
120) of non-adherent patients,13.3% (16/120) did not administer
their injections at the indicated hours, 2.5% (3/120) decided not to
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inject because of feeling better, and 5.8% (7/120) decided not to
inject because of feeling worse.
The percentage of doses received in the last month was 94.3%,
the average number of administered injections in that period was
14.262.1 (being 15 the expected doses), and 12.5% of the patients
administered less than 13 injections. The percentage of doses
received was higher among adherent patients according to MG
(96.2% vs. 90.2%, p = 0.0089), and only 28.0% of adherent
patients according to MG administered less than 15 injections.
Besides the MG test and the percentage of doses received, the
number of injections dispensed by the hospital pharmacy during
the six months period before the assessment was used as an
adherence measurement. The mean number of injections
dispensed by the hospital pharmacy was similar for all the six
months, being 89.7652.6 the total number of injections dispensed
at the end of the follow-up period. Nevertheless, 64.5% (60/93) of
patients had kept medication at home, being non-adherent
according to MG test criteria, the patients who tend to store
more injections (9.569.9 injections vs 5.766.1 injections).
Table 1. Demographic, clinical and clinical setting characteristics at baseline.
Demographics N=120
Age, years (mean 6 SD) 41.2611.2
Marital Status [N (%)]
Single 37 (30.8)
Married 75 (62.5)
Divorced 6 (5.0)
Widow/er 2 (1.7)
Education level [N (%)]
Primary 44 (36.7)
Secondary 45 (37.5)
University 31 (25.8)
Employment status [N (%)]
Active worker 40 (33.3)
Disabled 25 (20.8)
Housewife 23 (19.2)
Pensioner 14 (11.7)
Student 9 (7.5)
Unemployed 9 (7.5)
MS clinical factors N=120
MS diagnosis [N (%)]
RRMS 94 (78.3)
SPMS 22 (18.3)
CIS 4 (3.3)
Age at 1st episode (mean 6 SD) 29.569.1
Age at diagnosis (mean 6 SD) 32.269.8
Time since last episode (mean 6 SD) 3.163.5
EDSS score (mean 6 SD) 2.762.1
Anxiety/depression present [N (%)] 26 (21.7)
Regular fatigue present [N (%)] 56 (47.1)
Comorbidity present [N (%)]* 38 (31.7)
Hypertension [N (%)] 3 (8.1)
Clinical setting characteristics N=13
Centers with MS unit [N (%)] 6 (46.2)
Neurologists exclusively dedicated to MS [N (%)] 2 (15.4)
Centers with nurses exclusively dedicated to MS [N (%)] 10 (76.9)
Number of check-up during the first year of treatment (mean 6 SD) 3.161.4
Number of check-up during the second year of treatment (mean 6 SD) 2.660.8
RRMS: recurrent-remittent MS; SPMS: secondary-progressive MS; CIS: clinically isolated syndrome.
*Comorbidities are listed in Table 6.
doi:10.1371/journal.pone.0035600.t001
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Reasons for missing INFb-1b injections
The main reasons for missing INFb-1b injections are showed in
Table 2. Our results showed that the primary reason for missing
doses were forgetting injections (64.0%), followed by patient’s
decision (24.0%) and side effects (20.0%). None of the patients
missed injections due to perception of lack of efficacy.
Factors affecting adherence to INFb-1b
Our results demonstrated that none of the demographic and
clinical variables at baseline had a significant relationship with the
adherence to therapy, neither MS phenotype, nor time since first
and last episodes, or EDSS scores. Regarding clinical setting
characteristics, the proportion of adherent patients as assessed by
MG test and the percentage of doses received did not differ
between patients who were followed in centers with MS unit and
those who did not (Table 3).
General health status variables, INFb-1b treatment character-
istics, concomitant treatments, and adverse events did not show
any significant relationship with the proportion of adherent
patients (Table 4). Regarding adverse events, patients were more
adherent when they rarely or sometimes suffered from pain at the
injection site than when they suffered from pain more frequently
(p = 0.0486)[Table 4].
Multivariate analysis
The results of the multivariate regression model showed that,
among all the baseline variables, only age and the presence of
concomitant diseases were significant predictors of the number of
monthly injections (Table 5). According to this model, young
patients and patients who suffered from comorbidities (see Table 6)
were more likely to self-inject more doses, and, therefore to be
more adherent.
Safety
Most patients (77.5%) experienced at least one adverse event
during the previous month, mainly redness (59.1%) or pain
(52.5%) at site of injection. Other adverse events such as
inflammation at the injection site, muscular pain, headache, fever,
and shivering were less frequent.
Discussion
The results of this retrospective cross-sectional study showed
that 68% of patients adhered to INFb–1b treatment, both to the
dose and time recommended by their physician. Although the
minimum desirable levels of adherence in MS are currently
unknown, our results were below the 80% and 95% considered as
satisfactory in other chronic diseases [29]. Nevertheless, the
percentage of doses received yielded better results and reached
94% with 88% of patients injecting almost 87% of the intended
dose.
To date, several studies have been conducted on adherence to
DMD therapies for MS [15–25]. However, most of them have
been focused on discontinuation rates rather than on adherence to
prescribed doses [15–19,21,22]. To our knowledge, two studies
have assessed adherence to an intended number of doses [20], but
only the study of Devonshire et al. [25] evaluated adherence for a
month in patients on therapy for at least six months before the
study inclusion. Although the results of these authors were similar
to ours (70% of patients were adherent to INFb-1b treatment),
their definition of adherence was based on missing a single dose
without considering either adherence to timing or the overall
consumption of the prescribed doses. In the other study, in which
adherence to an intended number of doses was assessed [20],
adherence was defined also as missing a single dose but for a
longer period of time (six months) and in patients on therapy only
for the month before the study inclusion. The results of these
authors showed very low adherence rates (only 25% of patients
were adherent to INFb-1b), but their findings were not compa-
rable to ours because patients are more likely to miss doses and
withdraw treatment during the first six months of treatment [25].
Nevertheless, these authors found that the overall consumption of
the prescribed doses was good (88% of patients injected at least
80% of the intended dose). In fact, our results also showed that,
although a proportion of patients were considered as non-
adherent, their overall consumption of INFb-1b was good (above
the 80% of the prescribed dose). Interestingly, our results also
showed that a proportion of patients considered as adherent by
Morisky-Green test injected less than 15 injections per month.
This results show up that indirect measures of adherence such as
questioning the patient, although being relatively easily to use, can
be susceptible to misinterpretation and tended to overestimate the
patient’s adherence [29].
Besides MG test and the percentage of doses received, we used
the number of injections dispensed by the hospital pharmacy to
measure adherence. Among indirect methods to assess adherence
to medication regimens, rates of refilling prescriptions in a closed
pharmacy system are an alternative accurate measure of
adherence provided that refills are measured at several points of
time [29–31]. We found, however, that the monthly total number
of injections dispensed by the hospital pharmacy was not such an
accurate expected measure to assess therapeutic adherence. In
fact, although the amount of injections dispensed by the hospital
pharmacy was similar during the six months follow-up period of
the study, 65% of patients kept doses at home.
Table 2. Reasons for missing INFb-1b injections (N = 25).
N (%)
Forgetting injection 16 (64)
Own will decision 6 (24)
Adverse events
Fatigue 2 (8)
Flu symptoms 1 (4)
Headache 1 (4)
Infections 1 (4)
Avoid disturbances in social commitments 1 (4)
doi:10.1371/journal.pone.0035600.t002
Table 3. Adherence to INFb-1b treatment according to the
existence of an MS unit.
Existence of MS unit
Yes (N=67) No (N=53) p-value
Morisky-Green Test [N (%)] 0.2714*
Adherent 43 (64.2) 39 (73.6)
Non-adherent 24 (35.8) 14 (26.4)
Adherence rate (mean 6 SD) 93.33611.72 95.47611.90 0.3262{
*Chi-square test.
{ANOVA.
doi:10.1371/journal.pone.0035600.t003
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In this study, the primary reason for missing doses was
forgetfulness (64%), followed by patient’s decision (24%). The
recently reported results of Devonshire et al. [25] also found that
forgetting to administer injections was the most common reason
for missing injections. Some studies [25,24] suggested that
forgetting injections may be related to the complexity of treatment
regimens, lower cognitive function or other neuropsychological
problems such as depression. In our study, anxiety/depression
might have an effect on adherence because the proportion of
patients with those conditions was slightly higher among non-
adherent patients than among adherent patients. Taking into
account that patients with MS are likely to suffer from depressive
disorders [32] and that depression negatively affects adherence,
some authors have suggested that routinely screening for
depression and early treatment are interventions that might
enhance adherence to treatment [25,33,34]. Besides the screening
and treatment of these diseases, other interventions focused on
diminishing forgetfulness like regimen simplification or medication
reminders might also improve adherence.
We found that, although more than half of our patients suffered
from pain or redness at the injection site, these injection-related
events did not lead to skipping doses. Nonetheless, some studies
have found that injection-related issues such as adverse events at
the injection site, injection anxiety, or needle phobia usually led
patients to skip injections or to stop treatment [18,25,34]. For that
reason, interventions focused on making self-injection easier, and
the future availability of a non-injected therapy might improve
adherence [25,34].
Table 4. General health status variables and adverse events according to adherence as assessed by MG test.
Adherent Non-adherent p-value*
General health status, N 82 38
Presence of depression/anxiety [N (%)] 14 (17.1) 12 (31.6) 0.0728
Fatigue [N (%)] 36 (44.4)a 20 (52.6) 0.4042
Presence of comorbidities [N (%)] 23 (28.0) 15 (39.5) 0.2107
Concomitant treatments [N (%)] 41 (50.0) 19 (51.4) 0.8914
INFb-1b treatment characteristics
Time on INFb-1b treatment, years (mean 6 SD) 6.165.8 6.064.4 0.9273{
Presence of adverse events [N (%)] 62 (75.6) 31 (81.6) 0.4664
Pain at the injection site, N 42 21 0.0486
Rarely/sometimes [N (%)] 27 (64.3) 8 (38.1)
Very often/Always [N (%)] 15 (35.7) 13 (61.9)
Redness at the injection site, N 42 21 0.3534
Rarely/sometimes [N (%)] 27 (57.4) 11 (45.8)
Very often/Always [N (%)] 20 (42.6) 13 (54.2)
Inflammation at the injection site, N 26 19 0.0789
Rarely/sometimes [N (%)] 19 (73.1) 9 (47.4)
Very often/Always [N (%)] 7 (26.9) 10 (52.6)
Fever, N 18 10 0.4543
Rarely/sometimes [N (%)] 12 (66.7) 8 (80.0)
Very often/Always [N (%)] 6 (33.3) 2 (20.0)
Muscular pain, N 22 13 0.6891
Rarely/sometimes [N (%)] 15 (68.2) 8 (61.5)
Very often/Always [N (%)] 7 (31.8) 5 (38.5)
Shivering, N 27 11 0.6106
Rarely/sometimes [N (%)] 20 (74.1) 9 (81.8)
Very often/Always [N (%)] 7 (25.9) 2 (18.2)
Headache, N 30 13 0.3131
Rarely/sometimes [N (%)] 21 (70.0) 11 (84.6)
Very often/Always [N (%)] 9 (30.0) 2 (15.4)
aN = 81.
*Chi-square test.
{ANOVA.
doi:10.1371/journal.pone.0035600.t004
Table 5. Multivariate regression model for the number of
injections administered during the previous month.
N Estimator Standard Error p-value
Age 120 20.03742 0.01686 0.0283
Concomitant diseases 0.89561 0.40723 0.0298
doi:10.1371/journal.pone.0035600.t005
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Patient’s subtype of MS influences the likelihood of adherence
to therapy in terms of discontinuation [25]. In fact, the study of
Rı´o et al. [19] found that the proportion of patients stopping
DMD was significantly higher in patients with SPMS than in those
with RRMS. Although our study failed to find any relationship
between MS subtype and the number of injected medication, it
may be due to the small number of patients with SPMS and CIS
that were enrolled in the study.
An increased probability of adherence has also been associated
to the existence of a MS unit [25]. Moreover, thorough care and
service at the beginning of treatment, as well as educational
interventions to correct unrealistic improvement expectations,
indirectly increased adherence mainly because of the decreasing in
the dropout rates [19,35]. Nevertheless, our findings did not show
the expected trend because the proportion of patients who had
been treated in centers with MS unit, and who potentially might
have received better care and information on adherence and
treatment outcomes, had similar adherence outcomes than those
treated in centers without MS unit.
Our results demonstrated that none of the demographic and
clinical variables at baseline had a significant relationship with the
adherence to therapy, neither MS phenotype, nor time since first
and last episodes, or EDSS scores. Regarding clinical setting
characteristics, the proportion of adherent patients as assessed by
MG test and the percentage of doses received did not differ
between patients who were followed in centers with MS unit and
those who did not Finally, our multivariate analysis showed that
only age and comorbidities were significant predictors of the
overall number of injections administered in the previous month.
Although Reynolds et al. [22] demonstrated that patients below 34
years-old and those with cardiovascular comorbidities were more
likely to discontinue DMD therapies, the effect of these variables
on the overall number of injected doses or on the likelihood of
missing doses have never been found. In fact, only Tremlett et al.
[20] and Devonshire et al. [25] assessed predictors of adherence
(defined as missing a single dose), and found that the level of
education, duration of MS, time since last relapse, clinical setting
characteristics, history of missed doses, and alcohol consumption
predicted adherence in patients with MS. Our findings, thus,
pointed out that besides these variables, age and comorbidities also
have to be taken into account in the management of adherence in
patients with MS.
In summary, the results of this study highlighted the importance
of the methodology used to assess adherence to treatment in the
management of patients with MS in clinical practice. In fact,
although we found that the proportion of adherent patients was
not optimal, the overall consumption of the intended dose was.
Therefore, the number of injected doses or, alternatively, the
number of missed doses had to be taken into account when
predicting the consequences of poor adherence.
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Table 6. Comorbidity profile of the patients suffering from
MS (N = 37).
N (%)
Hyperlipoproteinemia 8 (21.6)
Hypertension 5 (17.5)
Rheumatoid arthritis 1 (2.7)
Diabetes mellitus 4 (10.8)
Migraine 3 (8.1)
Cardiac disorder 3 (8.1)
Trigeminal neuralgia 2 (5.4)
Thalassemia 2 (5.4)
Asthma 2 (5.4)
Atopy 1 (2.7)
Allergic conjunctivitis 1 (2.7)
Vitamin B12 deficiency 1 (2.7)
Me´nie`re’s disease 1 (2.7)
Epilepsy 1 (2.7)
Fibromialgy 1 (2.7)
Vertebral artrosis 1 (2.7)
Trigeminal neuralgia 1 (2.7)
Hypothyroidism 1 (2.7)
Urinary tract infection 1 (2.7)
Venous insufficiency 1 (2.7)
Mastectomy 1 (2.7)
Spinal disc herniation 1 (2.7)
Osteoarthritis 1 (2.7)
Osteoporosis 1 (2.7)
Sciatica 1 (2.7)
Sleep paralysis 1 (2.7)
Deep venous trombosis 1 (2.7)
Fibromialgy 1 (2.7)
Dysthymia 1 (2.7)
Hypophysiary bening tumor 1 (2.7)
Patients might have more than one comorbidity.
doi:10.1371/journal.pone.0035600.t006
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